Page last updated: 2024-11-02

pamidronate and Obesity

pamidronate has been researched along with Obesity in 1 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"In this study, cancer patients who had received zoledronate exhibited a significant 30-fold increase in their risk to develop ONJ."1.35Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. ( Dodson, TB; Wessel, JH; Zavras, AI, 2008)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wessel, JH1
Dodson, TB1
Zavras, AI1

Other Studies

1 other study available for pamidronate and Obesity

ArticleYear
Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:4

    Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Case-Control Studies; Co

2008